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Abstract
Nipsnap1 (4-nitrophenyl phosphatase domain and non-neuronal SNAP-25 like protein
homolog 1) is a novel mitochondrial protein that was shown to interact with the
intracellular domain of the Alzheimer’s Disease amyloid precursor protein (APP).
Genetic knock-down mouse model of the Nipsnap1 protein (NipKD) expression resulted
in a reduction of brain size and an increase in neuronal death measured by
immunohistochemical analyses (TUNEL, activated caspase 3, and FluoroJade-C
staining). In addition, there was a robust increase in activated Caspase 3 and FluoroJadeC staining in kainic acid treated NipKD brains compared to the WT brains. This work
provides the first evidence that Nipsnap1 plays an important role in the brain and that
disruption of Nipsnap1 expression causes neurodegeneration. Because Nipsnap1directly
interacts with APP, this work may provide new insights into the pathogenesis of
Alzheimer’s Disease and possibly new therapeutic strategies.
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GABA- Gamma-aminobutyric acid
GSSG- Glutathione Disulfide
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TUNEL- Terminal deoxynucleotidyl transferase dUTP
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NeuN- Neuronal nuclei
DAPI- 4’,6-diamidino-2-phenylindole
GFAP- Glial Fibrillary Acidic Protein
KA- Kainic acid
CA1- cornus ammonis, region I of hippocampus proper
CA2- cornus ammonis, region II of hippocampus proper
CA3- cornus ammonis, region III of hippocampus proper
DG- Dentate Gyrus
WT- Wildtype
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1. Introduction
Background
A. Alzheimer’s Disease
Alzheimer’s Disease (AD) is the leading cause of dementia, and is characterized
by a progressive decline in cognitive function, typically beginning with deterioration of
memory (Reitz et al., 2012). AD affects 10 to 20% of people older than 65 (Talmelli et
al., 2010). AD is the 6th leading cause of death in the United States, with someone
developing the disease every 67 seconds. In 2015, AD and other dementias cost the
United States $226 billion, with that cost potentially rising as high as $1.1 trillion by the
year 2050 (Alz.org). Pathologically, AD is characterized by massive extracellular
depositions of amyloid-beta (Aβ) plaques, which are generated by the proteolytic
cleaving of amyloid precursor protein (APP) (Selkoe, 1994; Yankner, 1996). Aβ plaques
are toxic to mitochondria and result in neuronal death, particularly affecting cortical and
hippocampal neurons. Apoptosis, also called programmed cell death, is a
morphologically distinct form of cell death. It is a highly regulated process that occurs
normally during development and is vitally important in maintaining cell populations.
Apoptosis is different from a process called necrosis, which is an uncontrolled cell death
typically due to direct damage to cellular membranes (Elmore et al, 2007). Furthermore,
Alzheimer’s Disease has been characterized as somewhat of an overlap of apoptosis and
necrosis, as hallmarks of both types of cell death can be found in AD tissue (Behl et al.,
2000).
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B. Amyloid Precursor Protein
The APP family proteins, including amyloid precursor-like protein-1 (APLP1)
and amyloid precursor-like protein-2 (APLP2), are transmembrane proteins that are
expressed in the developing and mature brain at the somal cell surface, along growing
axons and at the axonal growth cone (Selkoe, 2007). APP family proteins can processed
by α-secretase, β-secretase, and γ-secretase. During brain development, APP is typically
processed by α-secretase. α-secretase cleaves within the Aβ sequence, which releases a
soluble, amino-terminal APP fragment called APPS-α. APPS-α were shown to regulate
the function of APP in neurite outgrowth through the mechanism of competing with the
binding of APP to Itgβ (Young-Pearse, 2008).
When APP is cleaved normally by α-secretase, secreted forms of β-amyloid
precursor protein (sAPPs) are generated, which have been shown to have neuroprotective
and neurotrophic properties by a mechanism which may involve the stabilization of the
intraneuronal concentration of Ca2+ (Mattson et al, 1993).
When APP is aberrantly processed by β-secretase, Aβ peptides are generated,
which are 40-42 amino acid fragments. These Aβ peptides form aggregates, which are
called Aβ plaques. Aβ plaques are toxic to neurons through an interaction with Aβbinding alcohol dehydrogenases (ABAD) and Cyclophilin D (Cyp D) proteins, and result
in massive amounts of neuronal death over time, making them the hallmark of
Alzheimer’s Disease. Aβ peptides can induce apoptosis directly in cultured neurons by
sensitizing neurons to death by a lipid peroxidation mechanism (Loo, 1993).
After cleavage by β-secretase, an 83 amino acid carboxy-terminal fragment is left,
which is cleaved by γ-secretase. This cleavage by γ-secretase results in a free intracellular
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domain, Amyloid Precursor Protein Intracellular Domain (AICD). The AICD was shown
to induce significant changes in gene expression and neuron-specific apoptosis, which
suggests that APP possibly has a signaling mechanism closely linked with Alzheimer’s
Disease (Nagase, 2014).
The intracellular C-terminal domain of APP is highly conserved among the APP
family members, APLP1 and APLP2. Accumulation of AICD markedly activates
neuronal caspase-3 in a cleavage-dependent manner (Uetsuki, 1999). The AICD was
shown to induce significant changes in gene expression and neuron-specific apoptosis
(Nagase, 2014). γ-secretase has several substrates, including Notch, which then binds to
transcription factors, translocates to the nucleus and then regulates transcription of
enhancer of split complex genes (Greenwald, 1998). γ-secretase was shown to be
translocated to the nucleus by Fe65 adaptor where the APP-Fe65-Tip60 ternary complex
is formed and may activate transcription of target genes (Slomnicki, 2008) (Gao and
Pimplikar et al., 2001). This transcriptional activity that has a similar mechanism to the
Notch signaling pathway suggests that this signaling pathway may contribute to the γsecretase APP signaling, which may contribute to AD. The AICD was shown to
specifically induce neuronal apoptosis and dynamic changes in gene expression, which
included increased expression of 277 genes and decreased expression of 341 genes. This
suggests a correlation in the gene expression and neuronal specificity of cell death
induced by the AICD (Ohkawara, 2010). Furthermore, the AICD was shown to induce
neurotoxicity in rat primary cortical neurons by altering the expression of glycogen
synthase kinase 3β (GSK-3β), and forming a ternary complex with Fe65 and
CP2/LSF/LBP1 in the nucleus. This up-regulation of GSK-3β expression increases
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phosphorylation of tau, which is a substrate of GSK-3β in neurons (Kim et al., 2003).
Hyperphosphorylation of tau protein results in neurofibrillary tangles (NFTs), which are a
hallmark of AD and highly correlated with dementia (Wang JZ, 2013).
Studies in our laboratory have shown that AICD interacts with a novel protein, 4nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1
(Nipsnap1) (Tummala et al, 2010). The long-term goal of our lab is to investigate the role
of Nipsnap1 in AICD mediated neurotoxicity and AD.

C. Nipsnap1 background and overview
The molecular and cellular function of Nipsnap1 is not known. However, several
genomic or proteomic studies have identified Nipsnap1 levels to be affected under
different conditions. These studies provide some insights into the potential function of
Nipsnap1 and are briefly summarized below.

Using bioinformatic and biochemical approaches, it was previously reported that
the human NIPSNAP1 gene spans 26 kb of genomic sequence (Seroussi et al, 1998). The
Nipsnap1 gene was found to have a strong sequence similarity to chromosome III of
Caenorhabditis elegans, showing that the nipsnap1 gene is an evolutionarily well
conserved, novel gene family. Nipsnap1 was also found to have portions resembling a 4nitrophenyl phosphatase domain and non-neuronal SNAP 25-like protein (Seroussi et al,
1998).
Satoh et al. (2002) found that Nipsnap1 protein is localized in postsynaptic
density (PSD), which is a submembranous structure where neurotransmitters receptors
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are linked to the cytoskeleton and signaling molecules (Satoh et al, 2002). Interestingly,
Nipsnap1 levels were increased in the PSD after kainite stimulation, suggesting that
Nipsnap1 plays an important role in signal transduction and regulation of the
cytoskeleton in the PSD.
Using a combination of bioinformatics, pull-down assays and functional analysis
approaches, Nipsnap1 was identified in regulation of transient receptor potential vanilloid
channels 5 and 6 (TRPV 5/6), which is the most Ca2+ selective channel in the transient
receptor potential (TRP) protein superfamily. Nipsnap1 was shown to inhibit TRPV6
activity, suggesting that Nipsnap1 acts as an auxiliary protein (Schoeber et al., 2008).
In order to identify human liver proteins associated with liver development, a
proteomic approach was used that identified Nipsnap1 as having high expression before
16 weeks and then decreased expression between weeks 16 and 20 in the fetal liver
(Brizard et al., 2009). They showed that Nipsnap1 is stabilized at week 36 and
maintained throughout adulthood. These results suggest that Nipsnap1 plays an important
role in liver development.
Using a microarray approach, Surendran et al. (2005) found that Nipsnap1 levels
had a lower expression in a phenylketonuria (PKU) mouse brain. Because PKU in the
brain results in pathophysiological abnormalities including cognitive function, this
finding suggests that Nipsnap1 may have a role in memory and cognitive function
(Surendran et al, 2005).
Using an immunolocalization approach to investigate the distribution and
localization of Nipsnap1 in the brain, Nautiyal et al. (2010) found that Nipsnap1 is
expressed exclusively in neurons, including pyramidal neurons in the cerebral cortex,
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Purkinje neurons in the cerebellum, motor neurons in the spinal cord, dopaminergic
neurons in the midbrain and noradrenergic neurons in the brainstem (Nautiyal et al,
2010).
Because the x-box binding protein 1 (XBP1) plays a role in brain development
and involved in neurodegenerative and psychiatric diseases, a XBP1 knockout mouse was
generated to investigate behavioral phenotypes. The XBP1 knockout mouse showed
enhanced pre-pulse inhibition (PPI) activity. PPI is a measure of sensorimotor gating, and
occurs when a weak lead stimulus inhibits an intense stimulus (Swerdlow NR, 2013).
Nipsnap1 gene was strongly upregulated in the cortex and hippocampus, suggesting
Nipsnap1 impacts PPI (Takata et al, 2010).
Using high performance affinity beads, Nipsnap1 was found to interact with the
neuropeptide nocistatin (NST), suggesting that Nipsnap1 plays a crucial role in pain
transmission. Furthermore, the N-terminal truncated form of Nipsnap1 (29 kDA) was
found to be expressed in neuronal tissues, specifically synaptic membrane and
mitochondria of the brain (Okuda- Ashitaka et al, 2012).
In order to investigate chromosomal variants that could possibly contribute to
prostate cancer progression, the genome of a nonmalignant human prostate epithelial cell
line, RWPE1, was compared to the genome of a malignant, metastic derivative, WPE1NB26 (Malhotra et al, 2013). In the malignant cell line, NIPSNAP1 gene was inactivated.
Malhotra et al (2013) suggest that during the transition to malignancy, Nipsnap1 is not
present to inhibit TRPV6 activity, hence may have tumor suppressor activity
Lastly, using a functional proteomic approach, our group found that Nipsnap1
interacts with amyloid precursor protein (APP) (Tummala et al., 2013). Nipsnap1 was
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found to be targeted to the mitochondria via its N-terminal sequence. In addition,
Nipsnap1 was shown to interact with mitochondrial chaperone translocase of outer
membrane 22. Nipsnap1 mitochondrial localization was found to be critical for APP
interaction and over expression of APP disrupted mitochondria localization (Tummala et
al, 2013). These results suggest that Nipsnap1 may have a role in the mitochondria and its
interaction with APP may contribute to AD pathogenesis.

D. Role of Nipsnap1 in liver metabolism
Nipsnap1 is highly expressed in the liver and was shown to interact with
branched-chain α-ketoacid dehydrogenase complex (BCKDC) and pyruvate
dehydrogenase complex (PDC) complexes (Nauyital et al, 2010). In order to investigate
the physiological function of Nipsnap1, our lab generated a knockdown (KD) mouse
model using a retroviral gene trap strategy at the Texas Institute of Genomic Medicine
(TGIM, Houston, Texas). Liquid and gas chromatography approaches were used to
examine metabolic intermediates in NipKD and WT liver tissues (Goshal et al., 2014).
Forty-five metabolic intermediates were identified in mouse liver samples that exhibited
altered changes in NipKD livers compared to the WT. Specifically, 25 metabolites were
significantly up-regulated, 20 were significantly down-regulated, and 29 were marginally
altered. Most metabolite levels that were significantly altered belonged to lipid, amino
acid, nucleotide or carbohydrate metabolic pathways. Also, Nipsnap1 deficiency caused
an increase in utilization of fatty acid levels. Thirty-two carbohydrate intermediates were
affected by Nipsnap1 deficiency, and over one fourth were involved, in glycolysis,
gluconeogenesis and pyruvate metabolism. These findings suggested that Nipsnap1 may
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play a minor role in critical metabolic processes as opposed to a necessary catalytic
subunit. Importantly, Nipsnap1 deficiency resulted in an increase in glutathione (GSH), a
key antioxidant, and a decrease in glutathione disulfide (GSSG), a harmful, reduced form
of GSH. These results suggest that Nipsnap1 deficiency increases oxidative stress in the
liver (Ghoshal et al., 2014).

Significance
Mitochondrial dysfunction has been linked to ageing as well as to a number of
age-related neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s,
and amyotrophic lateral sclerosis (Lin and Beal, 2006; Mattson and Magnus, 2006; Schon
and Przedborski, 2011). Treatments that enhance mitochondrial function or reduce
oxidative stress have been shown to be effective in treating these diseases. Metabolic
dysfunction is linked to the progression of AD by an interaction between Aβ and ABAD
(Aβ-binding alcohol dehydrogenases) in the mitochondria. Aβ bound ABAD has been
shown to induce a change in the NAD binding site in ABAD (Lustbader JW, 2004). This
group also showed that Aβ bound ABAD resulted in exaggerated ROS production and
thus mitochondrial dysfunction (Lustbader JW, 2004).
Alzheimer’s Disease is the most common cause of dementia. Approximately four
million Americans suffer from AD, and the number of new cases is expected to double by
the year 2050. In December 2015, Congress approved a 60% increase in Alzheimer’s
Disease research funding, bringing the total to $936 million (AlzForum.org). However,
almost all drug development efforts are focused on inhibiting amyloid deposition in the
brain (Qian et al., 2015). However, these drugs have limited effectiveness in treating AD.
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Thus, identifying alternative therapeutic strategies for AD is very important. AICD has
also been shown to have toxic effects on neurons, but very little is known about the
cellular mechanisms of AICD toxicity. Because Nipsnap1 directly interacts with AICD
and that NipKD mice exhibit increased neurodegeneration, this work will provide a better
understanding of the role of Nipsnap1 in adult mice and may provide new insights into
the pathogenesis of AD and new therapeutic strategies.

Major Questions
NipKD brains are consistently smaller than C57/B6 wild-type brains based on
total brain weight measurements. The goal of my project was to investigate if this
difference in brain size is due to an increase in neurodegeneration in NipKD mice.
Specifically, my study focused on the following questions:

1. Does the NipKD brain have increased amounts of cell death, specifically
neuronal death?
2. Which major brain regions are affected by Nipsnap1 deficiency?
3. Does Nipsnap1 protect neurons from excitotoxicity?

To address these questions, I performed a series of immunohistochemical studies
to investigate apoptosis (measured by TUNEL and active caspase 3 staining) as well as
neurodegeneration (measured by FluoroJade-C staining). To determine if Nipsnap1 has a
role in neuroprotection, a pilot study was performed to examine neuronal degeneration in
one set of NipKD and WT animals after kainic acid injection.
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2. Methods
Animal Maintenance
A mouse model was generated with a disruption in the nipsnap1 gene using a
retroviral gene trap strategy (Ghoshal et al., 2013). NipKD and C57/B6 WT mice were
maintained in the University of Memphis animal facility according to the National
Research Council guidelines. Mice were separated by gender, with no more than five
mice in a conventional shoe-box sized cage. Each cage contained Teklad Aspen SaniChips bedding (Harlan Labratories, Indianapolis, IN). Food and water was available ad
libitum. All experimental procedures were done following the University of Memphis
Institutional Animal Care and Use Committee protocol (Protocol #0718).

Tissue Collection
A. Brain Weights
NipKD and C57/B6 mice were selected at different ages in order to compare brain
weights. Mice were anesthetized by intra-peritoneal injection of Avertin (40 mg/kg body
weight; Sigma) in PBS. Mice were euthanized by cervical dislocation before the entire
brain was removed, rinsed in PBS, and weighed (Mettler Tolendo XS204). Animals were
treated and handled exactly the same to minimize variability between the NipKD and WT
animals.
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B. Perfusion, Embedding and Sectioning
Six month old NipKD and C57 WT mice were used for immunofluorescence
experiments. Mice were cardiac perfused with 4% PFA in PBS and rinsed with PBS.
Brains were extracted and infiltrated using 15% sucrose for 2 hours, embedded in OCT
(Tissue Tek) and then frozen in a dry ice and methanol bath. Tissue sections were stored
at -80°C until use. Animals were treated and handled exactly the same to minimize
variability between NipKD and WT.

Immunofluorescence
Age-matched (6 months old) NipKD and C57 WT brains were sectioned using the
cryostat in 15µm sagittal sections using the Shandon Cryotome FE in the Histology Lab
at the Integrated Microscopy Center at the University of Memphis. Sections were dried
on the cryostat for 2 hours and then stored at -80°C until use. Sections were processed
using different antibodies and procedures as described below. All images were taken
using the Confocal Scanning Fluorescence Microscope Nikon Ti-E A1rS1 in the
Integrated Microscopy Center at the University of Memphis.

A. Active Caspase 3 and DAPI
To examine cell density and apoptosis in the NipKD and C57 brains, active
caspase 3 and DAPI staining was performed. NipKD (n=3) and WT (n=3) sections (3
sections per animal) were removed from the -80°C freezer and dried at room temperature
for one hour. After sections were dried, antigen retrieval was performed as follows.
Sections were hydrated in 2 changes of 100% ethanol for 3 minutes each, 95% and 80%
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ethanol for 1 minute each and then rinsed in distilled water. Sections were incubated with
1N HCl solution for 15 minutes, rinsed in two changes of PBS for 5 minutes each.
Sections were then blocked in 10% goat serum, 0.3% hydrogen peroxide in PBS at room
temperature for one hour. After blocking, sections were incubated with active caspase 3
antibody (1:1000, Abcam) and 10% goat serum in PBS overnight in a sealed moisture
box in the 4°C. The next morning, sections were washed in three changes of PBS for 10
minutes each. After washing, sections were incubated with Alexa Fluor 594-RB (1:1000,
Abcam) in 5% goat serum in PBS for one hour at room temperature. After secondary
antibody incubation, sections were washed in three changes of PBS for 10 minutes each,
and then mounted using Fluoroshield Mounting Medium containing DAPI (Abcam).
Sections were examined using Nikon Ti-E A1rS1 microscope with DAPI and TRITC
laser settings in NIS-Elements software. Pictures of the cortex were taken in 30 micron
intervals.

B. NeuN and Active Caspase 3
NipKD (n=3) and WT (n=3) sections (3 sections per animal) were removed from 80°C and dried at room temperature for one hour. After sections were dried, antigen
retrieval was performed as described above. Sections were then blocked in 10% goat
serum, 0.3% hydrogen peroxide in PBS at room temperature for one hour. After
blocking, sections were incubated with active caspase 3 antibody (1:1000, Abcam) and
10% goat serum in PBS overnight in a sealed moisture box in the 4°C. Sections were then
washed in three changes of PBS for 10 minutes each. After washing, sections were
incubated with NeuN antibody (1:800, Millipore) in 10% goat serum in PBS for one hour
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at room temperature. Sections were washed in three changes of PBS for 10 minutes each,
incubated with Alexa Fluor 488-MS and Alexa Fluor 594-RB (1:1000, Abcam) in 5%
goat serum in PBS for one hour at room temperature, and then washed in three changes
of PBS for 10 minutes each. After washing, sections were mounted using Fluoroshield
Mounting Medium containing DAPI (Abcam) and viewed using confocal microscopy as
described above in addition to FITC laser.

C. NeuN and DAPI
NipKD (n=3) and WT (n=3) sections (3 sections per animal) were removed from
the -80°C and dried at room temperature for one hour. After sections were dried, the
sections were washed in two changes of PBS for 5 minutes each. Sections were then
blocked in 0.3% hydrogen peroxide and 10% goat serum in PBS. After blocking, sections
were incubated in NeuN primary antibody (1:800, Millipore) in a moisture box in 4°C
overnight. The next day, sections were washed in three changes of PBS for ten minutes
each, and then incubated with Alexa Fluor 594-MS (1:1000) in 5% goat serum in PBS for
one hour at room temperature. After incubation of secondary antibody, sections were
washed three times in PBS for 10 minutes each. Sections were then mounted using
Fluoroshield Mounting Medium containing DAPI (Abcam). Sections were viewed using
confocal microscopy as described above.

D. GFAP and Active Caspase 3
Sections were removed from the -80°C and dried at room temperature for one
hour. Next, sections were washed in two changes of PBS for 5 minutes each, blocked in
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0.3% hydrogen peroxide at 10% goat serum in PBS, then incubated in GFAP antibody
(1:800, Chemicon) in a moisture box in 4°C overnight. The next day, sections were
washed in three changes of PBS for ten minutes each and then incubated with active
caspase 3 antibody (1:1000, Abcam) for one hour at room temperature. After active
caspase 3 incubation, sections were washed three times in PBS for 10 minutes each, then
incubated with Alexa Fluor 488-MS (1:000, Abcam) and Alexa Fluor 594-RB (1:000,
Abcam) in 5% goat serum in PBS for one hour at room temperature. After, sections were
washed three times in PBS for 10 minutes each, they were mounted using Fluoroshield
Mounting Medium containing DAPI (Abcam). Sections were viewed using confocal
microscopy as described above in addition to FITC laser.

TUNEL staining
NipKD (n=3) and WT (n=3) sections (3 sections per animal) were removed from
the -80°C and air dried at room temperature for one hour the sections were washed in two
changes of PBS for 5 minutes each. Sections were then blocked in 0.3% hydrogen
peroxide and 10% goat serum in PBS. After blocking, sections were incubated in NeuN
primary antibody (1:800, Millipore) in a moisture box in 4°C overnight. The next day,
sections were washed in three changes of PBS for ten minutes each, then incubated with
Alexa Fluor 594-MS (1:1000, Abcam) in 5% goat serum in PBS for one hour at room
temperature. After incubation of secondary antibody, sections were washed three times in
PBS for 10 minutes each. TUNEL staining was then performed following manufacturer’s
protocol (Roche) and were then mounted using Fluoroshield Mounting Medium
containing DAPI (Abcam). Sections were viewed using confocal microscopy as

	
  

18	
  	
  

	
  
	
  
described above in addition to FITC laser. Figure 1 is an example of how TUNEL+
counting was performed.
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Figure 1. Example of the procedure for counting TUNEL (green) and DAPI (blue)
positive cells in the brain, 40X objective. Cells were counted TUNEL+ if there was
TUNEL staining (DNA fragmentation) co-localized with DAPI, which is a nuclear
stain. The arrows indicated cells that were counted as TUNEL+. The circles indicate
cells that were not counted as TUNEL+.
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FluoroJade-C staining
FluoroJade-C is a neuron specific stain that identifies degeneration regardless of
specific treatment or mechanism (Schmued et al., 2005). Sections were removed from the
-80°C and dried at room temperature overnight. The next day, sections were immersed in
100% EtOH for 3 minutes, 70% for 1 minute, then dH2O for 1 minute. Then, sections
were immersed in 0.06% potassium permanganate for 15 minutes and placed on a shaker
at 50 RPM. After KMNO4 immersion, sections were rinsed in dH2O for 1 minute. Then,
sections were immersed in 0.001% FluoroJade-C solution for 30 minutes and placed on a
shaker at 50 RPM. Next, sections were rinsed in three changes of dH2O for 1 minute
each. After rinsing, slides were placed on a paper towel in an empty, dark drawer to dry
overnight. The next day, slides were immersed in three changes of xylene for 2 minutes
each, then mounted using Fluoroshield Mounting Medium containing DAPI (Abcam).
Sections were viewed using confocal microscopy with DAPI and FITC laser settings.
Kainic Acid Treatment
Age matched 6 month old mice were given a single, intraperitoneal injection of
kainic acid (30 mg/kg body weight) monohydrate solution in PBS (Sigma) by Sarani
Ghoshal, a former graduate student in the lab. Two hours post injection, mice were
monitored for seizure behavior. Mice were then perfused, brains were collected and
cryoprotected using sucrose. After cryoprotection, brains were embedded in OCT (Tissue
Tek) and stored in the -80°C freezer until sectioning.

	
  

	
  
	
  
3. Results
NipKD brains weigh less than WT brains
Upon initial examination of the NipKD brains, it appeared that the KD brains
were generally smaller than their WT littermates. To quantify this observation, NipKD
and C57/B6 WT brains were weighed at various time points, ranging from P76 to P197
(Figure 2). NipKD brains consistently weighed less than the WT animal, particularly at
younger ages. However, NipKD brains weights increased at a quicker rate than the WT.
We chose to perform subsequent experiments on six month (180 day) old animals since
there was a substantial difference in brain sizes (weights) at this time, when mice are
sexually mature young adults. By focusing on this age range, we aimed to avoid potential
physiological complications due to development or aging.

Qualitative analysis of apoptosis in NipKD brain
The difference in brain sizes between NipKD and WT animals could be due to a
lower rate of cell proliferation/differentiation or increased rate of cell death in the NipKD
animals. To address this issue, NipKD and WT brain sections were stained using active
caspase 3 in order to detect apoptosis. Qualitatively, the cerebellum and CA1 region of
the hippocampus showed minimal levels of apoptosis in both NipKD and WT brains
(Figure 3,4). Also, in the hippocampus CA2 and CA3 regions, NipKD animals had a
lower cell density, measured by DAPI staining, compared to the WT, although they did
not exhibit a qualitative difference in the level of apoptosis (Figures 5, 6). Since the CA2
and CA3 regions of the hippocampus are primarily pyramidal neurons and lack glial
cells, these results suggested that neurons might be selectively undergoing apoptosis in
NipKD brain. Also the dentate gyrus of the NipKD hippocampus seemed to have a
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slightly elevated level of active caspase 3 cells relative to the WT (Figure 7). Futhermore,
the NipKD cortex had a noticeable increase in apoptosis compared to WT animals
(Figure 8). To explore if there was any glial cells death in the cortex, apoptosis was
examined in glial cells using GFAP marker staining. We found that none of the active
caspase 3 positive cells were stained with GFAP in the NipKD cortex (Figure 9). Taken
together, these results suggested that cortical and hippocampal neurons in NipKD brains
were susceptible to programmed cell death. To investigate if these differences in
apoptosis were statistically significant, we analyzed three different animals, quantified
the staining and performed statistical analysis as shown below.
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Figure 2. NipKD and WT brain weights at various ages. Each symbol represents one
animal. The regression line is shown separately for WT (blue diamond) and NipKD
(red square) animals.

	
  

24	
  	
  

	
  
	
  

Figure 3. Active caspase 3 expression in the cerebellum of 6 mo NipKD and WT mice, 40X
objective. Sagittal, 15µm sections were stained as follows. A: DAPI (blue) and active
caspase 3 (red) expression in the WT cerebellum. B: Active caspase 3 expression (red) in
the WT cerebellum. C: DAPI (blue) and active caspase 3 (red) expression in the NipKD
cerebellum. D: Active caspase 3 (red) in the NipKD cerebellum. The WT and NipKD
cerebellums both appeared to be healthy with minimal apoptosis.
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Figure 4. Active Caspase 3 expression in the hippocampal CA1 region of 6 mo NipKD and
WT mice, 40X objective. Sagittal, 15µm sections were stained as follows. A: DAPI (blue)
and active caspase 3 (red) expression in CA1 region of the WT hippocampus. B: Active
caspase 3 expression (red) in the CA1 region of the WT hippocampus. C: DAPI (blue) and
active caspase 3 (red) expression in the CA1 region of the NipKD hippocampus. D: Active
caspase 3 (red) in the CA1 region of the NipKD hippocampus. Qualitatively, the number of
DAPI positive cells and Caspase 3 positive cells appeared to be similar in both the WT and
NipKD.
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Figure 5. Active Caspase 3 expression in the hippocampal CA2 region of 6 mo NipKD and
WT mice, 40X objective. Sagittal, 15µm sections were stained as follows. A: DAPI (blue)
and active caspase 3 (red) expression in CA2 region of the WT hippocampus. B: Active
caspase 3 expression (red) in the CA2 region of the WT hippocampus. C: DAPI (blue) and
active caspase 3 expression in the CA2 region of the NipKD hippocampus. D: Active
caspase 3 (red) expression in the CA2 region of the NipKD hippocampus. Qualitatively,
there was an increase in active caspase 3+ cells in the CA2 region of the NipKD brain.
Furthermore, the NipKD CA2 region appeared to have less healthy, rounded cells with an
increase in apoptotic bodies.
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Figure 6. Active caspase 3 expression in the CA3 region of 6 mo NipKD and WT mice, 40X
objective. Sagittal, 15µm sections were stained as follows. A: DAPI (blue) and active
caspase 3 (red) expression in CA3 region of the WT hippocampus. B: Active caspase 3
expression (red) in the CA3 region of the WT hippocampus. C: DAPI (blue) and active
caspase 3 (red) expression in the CA3 region of the NipKD hippocampus. D: Active caspase
3 (red) in the CA3 region of the NipKD hippocampus. Qualitatively, the NipKD CA3 region
appeared less healthy, with a visually noticeable decrease in density of DAPI+ cells.
However, the WT CA3 appeared healthy, but had more caspase 3+ cells.
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Figure 7. Active caspase 3 expression in the DG region of 6 mo NipKD and WT mice, 40X
objective. Sagittal, 15µm sections were stained as follows. A: DAPI (blue) and active
caspase 3 (red) expression in the dentate gyrus region of the WT hippocampus. B: Active
caspase 3 expression (red) in the dentate gyrus region of the WT hippocampus. C: DAPI
(blue) and active caspase 3 (red) expression in the dentate gyrus region of the NipKD
hippocampus. D: Active caspase (red) in the dentate gyrus region of the NipKD
hippocampus. Qualitatively, the NipKD dentate gyrus had more active caspase 3+ cells.
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Figure 8. Active caspase 3 expression in the frontal cortex of the NipKD and WT, 40X
objective. Sagittal, 15µm sections were stained as follows. A: DAPI (blue) and active
caspase 3 (red) expression in the WT cortex. B: Active caspase 3 expression (red) in the WT
cortex. C: DAPI (blue) and active caspase 3 (red) expression in the NipKD cortex. D:
Active caspase 3 (red) in the NipKD cortex. Qualitatively, the NipKD cortex has a visually
noticeable increase in active caspase 3+ cells. Because there was more of an increase in
active caspase 3+ cells in the NipKD cortex more than any other examined brain structure,
a more in depth examination of cortical apoptosis was performed.
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Nipsnap1 deficiency results in significantly higher apoptosis in cortical
neurons
In the previous section, based on the qualitative survey of apoptosis in various
brain regions, we determined that the biggest differences in apoptosis were in cortical
regions and hippocampus. In this section, we focused on these regions for a deeper
quantitative analysis. Active caspase 3, NeuN and DAPI staining was performed on three
different six month old NipKD and WT animals. There was a statistically (p< 0.012, two
tailed Student’s t-test, n=3) significant increase in active caspase 3+ neurons in NipKD
brain (Figure 10,11) per 0.024 mm2.
Since activation of Caspase 3 occurs during the early stages of apoptosis, we
investigated if late stage apoptosis was also increased in NipKD mice using the TUNEL
assay. Consistent with the active caspase 3 staining, there was a statistically significant
(p<0.007, two-tailed Student’s t-test, n=3) increase in TUNEL+ neurons in six month old
NipKD cortex compared to age-matched WT animals (Figures 12,13) per 0.024 mm2.
In order to identify neurons that were undergoing other types of degeneration,
FluoroJade-C staining was performed. It is worth mentioning that there was elevated nonspecific binding of FluoroJade-C in the meninges in both brain types. Qualitatively, there
were more neurons undergoing degeneration in the NipKD cortex compared to the WT
(Figure 14). In addition to early stages of apoptosis, Nipsnap1 deficiency appeared to
increase degeneration of neurons, regardless of the mechanism by which the cell was
dying, either by necrosis or apoptosis.
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These results indicate that neurons are selectively sensitive to Nipsnap1
deficiency. To test this further, I quantified the number of NeuN and DAPI positive cells.
Consistent with the active caspase 3 results, NipKD animals had a nearly significant
(p<0.07, two-tailed Student’s t-test, n=3) (Figures 15,16) per 0.039 mm2.
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Figure 9. Active Caspase 3, GFAP and DAPI expression in the frontal cortex of the NipKD and
WT, 40X objective. Sagittal, 15µm sections were stained as follows. A: GFAP (green) and active
caspase 3 expression (red) in the WT cortex. B: DAPI (blue), GFAP (green) and active caspase 3
(red) expression in the WT cortex. C: GFAP (green) and active caspase 3 expression (red) in the
NipKD cortex. D: DAPI (blue), GFAP (green) and active caspase 3 (red) expression in the NipKD
cortex. There were no GFAP+ cells undergoing apoptosis in either mouse strain.
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Figure 10. NeuN, Active Caspase 3 and DAPI staining in 6 month old WT and NipKD
cortices, 40X objective. Sagittal, 15µm sections were stained as follows. A: DAPI (blue) and
active caspase 3 (red) in the WT frontal cortex. B: Active caspase 3 (white) in the WT
frontal cortex. C: DAPI (blue), active caspase 3 (red) and Neu N (green) in the WT frontal
cortex. D: A: DAPI (blue) and active caspase 3 (red) in the NipKD frontal cortex. E: Active
caspase 3 (white) in the NipKD frontal cortex. F: DAPI (blue), active caspase 3 (red) and
Neu N (green) in the NipKD frontal cortex. The NipKD cortices consistently had an
increase in active caspase 3+ neurons in the frontal cortex.
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Figure 11. Quantitative analysis of active caspase 3+ neurons in WT and NipKD Cortex.
NipKD cortices (n=3) had about a three-fold increase in active caspase 3+ neurons
compared to the WT cortices (n=3). *, p< 0.012, (two-tailed Student’s t-test).
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Figure 12. TUNEL, DAPI and NeuN staining in WT and NipKD cortices, 40X objective.
Sagittal, 15µm sections were stained as follows. A: TUNEL staining (green) and DAPI
(blue) in the WT frontal cortex. B: TUNEL staining (green) in the WT cortex. C: TUNEL
staining (green), DAPI (blue) and NeuN (red) staining in the WT cortex. D: TUNEL
staining (green) and DAPI (blue) in the NipKD frontal cortex. E: TUNEL staining (green)
in the NipKD cortex. F: TUNEL staining (green), DAPI (blue) and NeuN (red) staining in
the NipKD cortex. NipKD frontal cortices consistently had an increase in TUNEL+
neurons compared to the WT.
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Figure 13. Quantitation of TUNEL positive neurons in the WT and NipKD cortices. The
NipKD frontal cortices (n=3) had a statistically significant increase in TUNEL+ neurons
compared to the WT frontal cortices (n=3). *, p < 0.007, (two-tailed Student’s t-test).
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Figure 14. DAPI and FluoroJade-C staining in the WT and NipKD frontal cortices, 40X
objective. Sagittal sections were stained as follows. A: DAPI (blue) expression in the WT
frontal cortex. B: FluoroJade-C staining (green) in the WT frontal cortex. C: DAPI (blue)
expression and FluoroJade-C staining (green) in the WT frontal cortex. D: DAPI (blue)
expression in the NipKD frontal cortex. E: FluoroJade-C staining (green) in the NipKD
frontal cortex. F: DAPI (blue) expression and FluoroJade-C staining (green) in the NipKD
frontal cortex. Qualitatively, the NipKD frontal cortex has a substantial increase in
FluoroJade-C+ cells, indicating a higher amount of neurodegeneration in NipKD cortex.
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Figure 15. DAPI and NeuN staining in the frontal cortex of 6 month old WT and NipKD
brains, 20X objective. Sagittal sections were stained as follows. A: DAPI (blue) expression
in the WT frontal cortex. B: NeuN (red) expression in the WT frontal cortex. C: DAPI
(blue) and NeuN (red) expression in the WT frontal cortex. D: DAPI (blue) expression in
the NipKD frontal cortex. E: NeuN (red) expression in the NipKD frontal cortex. F: DAPI
(blue) and NeuN (red) expression in the NipKD frontal cortex.
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Figure 16. DAPI+ and NeuN+ cells in the WT and NipKD cortices. The NipKD frontal
cortex (n=3) had a slight decrease in NeuN+ cells, and had an approaching significant (p <
0.070213, Student’s t-test) decrease in total DAPI+ cells compared to WT frontal cortex
(n=3).
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Kainic Acid induced NipKD brains have increased cortical and hippocampal
cell death compared to WT
In the previous sections, I showed that Nipsnap1 deficiency causes neuronal
death, suggesting that Nipsnap1 plays a protective role in neurons. To test this hypothesis
further, we performed preliminary studies after treating NipKD and WT animals with an
excitotoxic agent, kainic acid. The effects of kainic acid have been well documented in
mouse brain (Zheng et al., 2011). In a C57/B6 WT mouse brain, the increased DNA
fragmentation is found in the hippocampus, particularly the CA1 and CA3 (Hu et al,
1998). Six month old NipKD and C57/B6 WT mice were given a single intraperitoneal
injection of kainic acid (30 mg/kg), perfused and cryoprotected after two hours, and
apoptosis was examined using immunohistochemical techniques. As expected, kainic
acid increased apoptosis in the brain. Interestingly, in the NipKD cortex, there was a
modest increase of active caspase 3 cells compared to the WT control animals (Figure
17). In the dentate gyrus region of the hippocampus, there was an increase in active
caspase 3 expression in the NipKD (Figure 18). In the CA1 region of the hippocampus,
there was a slight increase in active caspase 3 expression in the NipKD brain (Figure 19).
Furthermore, DAPI+ cells in the NipKD looked morphologically disheveled compared to
the WT, suggesting later stages of apoptosis. Moreover, the CA1 region structure was
less pronounced than the WT. In the CA2 region of the hippocampus, there was a large
increase of active caspase 3 expression and apoptotic bodies, with virtually no apoptosis
occurring in the WT (Figure 20). In the CA3 region of the hippocampus, there was a
slight increase of active caspase 3 expression in the NipKD brain (Figure 21).
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Next, I examined if general neurodegeneration, measured by FluoroJade-C staining, was
also increased in NipKD animals after KA treatment. In the cortex, there was a noticeable
increase of FluoroJade-C+ neurons in the NipKD, indicating an increase of late stage
degeneration (Figure 17). Similarly, the dentate gyrus and CA1 regions of the
hippocampus showed an increase of FluoroJade-C+ staining (Figures 18, 19). In the CA2
region of the hippocampus, the NipKD had an increase of FluoroJade-C+ neurons
compared to the WT (Figure 20). In contrast, the CA3 region the hippocampus, the
NipKD brain had a slight increase in degenerating neurons compared to the WT (Figure
21).
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Figure 17. Active caspase 3, FluoroJade-C+ and DAPI staining with kainic acid treatment
in the WT and NipKD frontal cortices, 40X objective. Sagittal sections were stained as
follows. A: DAPI (blue) and active caspase 3 expression (red) in the kainic acid induced
WT frontal cortex. B: Active caspase 3 expression (white) in the kainic acid induced WT
frontal cortex. C: DAPI (blue) and FluoroJade-C (green) expression the kainic acid
induced WT frontal cortex. D: FluoroJade-C (green) expression in the kainic acid induced
WT frontal cortex. E: DAPI (blue) and active caspase 3 expression (red) in the kainic acid
induced NipKD frontal cortex. F: Active caspase 3 expression (white) in the kainic acid
induced NipKD frontal cortex. G: DAPI (blue) and FluoroJade-C (green) expression the
kainic acid induced NipKD frontal cortex. H: FluoroJade-C (green) expression in the
kainic acid induced NipKD frontal cortex. Qualitatively, there was a difference in the
number of active caspase 3+ cells and FluoroJade-C cells between the WT and NipKD
cortices.
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Figure 18. Active caspase 3+ and FluoroJade-C+ staining with DAPI staining with kainic
acid treatment in the dentate gyrus, 40X objective. Sagittal sections were stained as follows.
A: DAPI (blue) and active caspase 3 expression (red) in the kainic acid induced WT dentate
gyrus. B: Active caspase 3 expression (white) in the kainic acid induced WT dentate gyrus.
C: DAPI (blue) and FluoroJade-C (green) expression the kainic acid induced WT dentate
gyrus. D: FluoroJade-C (green) expression in the kainic acid induced WT dentate gyrus. E:
DAPI (blue) and active caspase 3 expression (red) in the kainic acid induced NipKD
dentate gyrus. F: Active caspase 3 expression (white) in the kainic acid induced NipKD
dentate gyrus. G: DAPI (blue) and FluoroJade-C (green) expression the kainic acid
induced NipKD dentate gyrus. H: FluoroJade-C (green) expression in the kainic acid
induced NipKD dentate gyrus. The NipKD dentate gyrus shows an increase in active
caspase 3+ cells and a robust increase FluoroJade-C+ cells.
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Figure 19. Active caspase 3+ and FluoroJade-C+ staining with DAPI staining with kainic
acid treatment in the CA1 region of the hippocampus, 40X objective. Sagittal, 15µm
sections. A: DAPI (blue) and active caspase 3 expression (red) in the kainic acid induced
WT CA1. B: Active caspase 3 expression (white) in the kainic acid induced WT CA1. C:
DAPI (blue) and FluoroJade-C (green) expression the kainic acid induced WT CA1. D:
FluoroJade-C (green) expression in the kainic acid induced WT CA1. E: DAPI (blue) and
active caspase 3 expression (red) in the kainic acid induced NipKD CA1. F: Active caspase
3 expression (white) in the kainic acid induced NipKD CA1. G: DAPI (blue) and
FluoroJade-C (green) expression the kainic acid induced NipKD CA1. H: FluoroJade-C
(green) expression in the kainic acid induced NipKD CA1. The WT and NipKD CA1
regions both show similar amounts of active caspase 3+ cells. The WT and NipKD CA1
both show large amounts of FluoroJade-C+ neurons. However, the WT CA1 has stronger
FluoroJade-C staining, possibly indicating a later stage in neurodegeneration.
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Figure 20. Active caspase 3+ and FluoroJade-C+ staining with DAPI with kainic acid
treatment in the CA2 region of the hippocampus, 40X objective. Sagittal, 15µm sections. A:
DAPI (blue) and active caspase 3 expression (red) in the kainic acid induced WT CA2. B:
Active caspase 3 expression (white) in the kainic acid induced WT CA2. C: DAPI (blue)
and FluoroJade-C (green) expression the kainic acid induced WT CA2. D: FluoroJade-C
(green) expression in the kainic acid induced WT CA2. E: DAPI (blue) and active caspase 3
expression (red) in the kainic acid induced NipKD CA2. F: Active caspase 3 expression
(white) in the kainic acid induced NipKD CA2. G: DAPI (blue) and FluoroJade-C (green)
expression the kainic acid induced NipKD CA2. H: FluoroJade-C (green) expression in the
kainic acid induced NipKD CA2. The NipKD CA2 region shows an increase in active
caspase 3+ cells. However, both cortices have large amounts of FluoroJade-C positive
neurons. The NipKD CA2 region appears to have less cell density and increase in visually
unhealthy cells.
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Figure 21. Active caspase 3+ and FluoroJade-C+ staining with DAPI with kainic acid
treatment in the CA3 region of the hippocampus, 40X objective. Sagittal, 15µm sections. A:
DAPI (blue) and active caspase 3 expression (red) in the kainic acid induced WT CA3. B:
Active caspase 3 expression (white) in the kainic acid induced WT CA3. C: DAPI (blue)
and FluoroJade-C (green) expression the kainic acid induced WT CA3. D: FluoroJade-C
(green) expression in the kainic acid induced WT CA3. E: DAPI (blue) and active caspase
3 expression (red) in the kainic acid induced NipKD CA3. F: Active caspase 3 expression
(white) in the kainic acid induced NipKD CA3. G: DAPI (blue) and FluoroJade-C (green)
expression the kainic acid induced NipKD CA3. H: FluoroJade-C (green) expression in
the kainic acid induced NipKD CA3.The WT and NipKD CA3 regions both showed
minimal and similar amounts of active caspase 3+ and FluoroJade-C+ cells.
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4. Discussion
Previously, our group has shown that Nipsnap1 is a mitochondrial protein that
interacts with AICD, which is the intracellular component of APP. AICD has been linked
to cellular toxicity and disruption of mitochondrial function associated with Alzheimer’s
Disease. Mitochondrial dysfunction is one of the major components of AD, resulting in
the loss of neurons. The normal physiological role of Nipsnap1 is unknown. In order to
further investigate the role of Nipsnap1, our lab previously generated a mouse model with
a Nipsnap1 deficiency. My studies focused on characterization of the effects of Nipsnap1
deficiency in the brain.
My studies showed that NipKD brains were consistently smaller than WT brains
at various post-natal ages (Figure 2). However, the NipKD brains seem to be growing at a
quicker rate over time than the WT mice, potentially making up for the loss of brain
volume that seems to be occurring during early development. It is worth noting that based
on the observed weight trajectories, it is possible that NipKD mice brain weights catch up
with WT brain after postnatal day 300. However, this does not account for the ventricular
volume in the brains. Due to time limitations and availability of animals, I did not extend
these initial data to very early post-natal and late adulthood ages. However, my
preliminary results indicate that Nipsnap1 deficiency has a greater impact on brain size
(weight) early during development than in late adulthood. The precise mechanism for the
early difference and also the apparent catch-up rate of brain weights is not known at this
time.
My studies indicate that Nipsnap1 deficiency increases neuronal apoptosis and
neurodegeneration in the cortex. Although Nipsnap1 is expressed in the cerebellar
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neurons, I did not detect any major differences in the number of apoptotic neurons in the
cerebellum. In contrast, I did find a significant increase in apoptotic neurons in cortex.
This finding suggests that cortical neurons are more sensitive to Nipsnap1 deficiency.
Cortical neurons are primarily GABAergic and cholinergic (Jones EG, 1986). My results
are intriguing in light of previous reports that Aβ specifically induces cholinergic cell
loss (Satyabrata et al., 2004). It would be interesting, in future studies, to determine
whether the cortical neurons that are undergoing apoptosis in the NipKD brain are
cholinergic. Taken together, these results suggest that cholinergic neurons in the cortex
may be more sensitive to Nipsnap1 deficiency and that perhaps an interaction between
AICD and Nipsnap1 could provide a molecular mechanism by which Aβ and AICD
selectively damage cholinergic neurons in AD brain.
Because of the increased apoptosis occurring in the frontal cortex of the NipKD
brains, it was important to differentiate which cell types were dying. Visually, the glial
cell density was similar in each strain, although the glial cell distribution was different
and seemed be more dense in the upper layers of the NipKD cortex. Qualitative analysis
showed that there were virtually no glial cells, which were positive for active caspase 3 in
either the NipKD or WT brain. This is an important finding because Nipsnap1 has been
shown to be neuron specific (Tummala et al., 2010) and involved in metabolism of
neurons (Nautiyal et al., 2010). The seemingly rapid increase in brain weight in the
NipKD animal suggests that there could potentially be an increase in glial cell
proliferation. Glial cells are vitally important for neuronal maintenance. It is possible that
in NipKD brains, glial cell proliferation is increased as a compensatory mechanism to
keep the remaining neurons healthy. Future experiments would be needed to quantify the
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number of GFAP positive cells and to test whether glial cells account for the rapid
increase in brain weights of NipKD animals. Our observation that glial cells do not
undergo apoptosis in NipKD mice suggest that Nipsnap1 may not be involved in this
aspect of AD pathogenesis.
Immunohistochemical detection of apoptosis can be technically variable.
Considering apoptosis occurs over a 24 hour period and diseases like AD are
progressively deteriorative, it was important to examine both early stages and late stages
of apoptosis. Thus, in my studies, the increase in cellular death in NipKD brains was
confirmed using two different markers for apoptosis: active caspase 3 for early apoptosis
and TUNEL staining for later stages of apoptosis. Caspase 3 is activated by caspase 9,
after the formation of APAF-1 and the release of cytochrome c from the mitochondria,
before cells undergo the degradation phase (Mattson, 2000). Active caspase 3 was used
because once caspases are activated in the apoptosis pathway, cells are committed to die
(Elmore et al., 2007). Upon examination of the NipKD and WT cortices, there was a
statistically significant increase of active caspase 3+ neurons. TUNEL staining
enzymatically end-labels DNA strand breaks (Elmore et al., 2007). Because degradation
of DNA is the major characteristics of cells undergoing apoptosis, this assay is a
beneficial tool in identifying cells undergoing late stages of apoptosis (Kyrylkova et al.,
2012). Age matched NipKD and WT brains were examined using TUNEL and NeuN as a
counterstain in order to verify the neuron specificity of the cells dying. Upon examination
of the NipKD and WT cortices, there was a statistically significant increase in TUNEL+
neurons. Taken together, my observations that both activation of caspase 3 and TUNEL
staining was significantly increased in NipKD brains, allows us to be confident that
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Nipsnap1 deficiency increases apoptosis in the brain. This conclusion was further
confirmed using a different marker, FluoroJade-C, which labels degenerating neurons.
Although we observed an increase in the number of apoptotic neurons, this
increase does not account for the large difference in brain weights at early developmental
ages. There are a few possible explanations for this observation. First, it is possible that
the rate of apoptosis is higher early after birth and decreases during adulthood. There is
some evidence to support this possibility, because we saw fewer cells in the CA2, but
essentially no cells undergoing apoptosis. However, this explanation is counter-intuitive
to AD and the aging hypothesis because AD is a progressive, neurodegenerative disease
that typically starts to occur during adulthood instead of earlier in life. Secondly, the
decrease in DAPI+ cells in the six month NipKD was approaching statistical significance,
which could account for the difference in brain weights at earlier ages. It would be
interesting in future studies to collect brains during earlier stages of development to
survey the effects Nipsnap1 has on neuronal and glial densities in major brain structures.
The most visually apparent difference in the NipKD brain compared to the WT
brain was the decrease of cell density in the NipKD cortex. Based on sampling from three
different six-month old animals, NipKD cortices had an average of 65.6 neurons
compared to the 103.8 neurons in the WT per 0.039 mm2. Although this is not
statistically significant, a reduction in neuronal numbers in the NipKD animal is an
important finding because the cortex undergoes severe, progressive atrophy in AD
patients, which results in significant loss of synapses (DeKosky et al., 1990). This is
interesting finding because there is no glial cell death in either mice strain at 6 months of
age. This data further suggests that there is potentially some kind of early developmental
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cell death occurring in the NipKD animal. Another interesting observation is the increase
of DAPI+ cells that were highly fragmented, which is an indication that the cells are
undergoing late stages of apoptosis. Qualitatively, more NeuN+ cells had distorted nuclei,
suggesting that more neurons were undergoing later stages of apoptosis in the NipKD
frontal cortex than was detected by the TUNEL assay.
Because of Nipsnap1’s apparent role in neuron viability, the next step was to
examine if Nipsnap1 possess neuroprotective features. To address this issue, six month
WT and NipKD animals were given the toxic treatment of kainic acid, which causes
severe neuronal loss in the hippocampus and frontal cortex relative to the WT. There was
a qualitatively consistent increase in active caspase 3 cells in the NipKD brain in the
following brain regions: cortex, dentate gyrus, CA1, CA2 and CA3 of the hippocampus.
Similarly, all of these regions, except for CA2 region of the hippocampus, showed a
qualitative increase in FluoroJade-C staining. Interestingly, CA1 and CA3 neurons have
been shown to be significantly reduced in AD patients, so seeing an increase in overall
degeneration in these areas correlates with those findings (Padurariu et al., 2012).
Moreover, the CA1 region of the hippocampus has been shown to be affected by
neuronal loss in AD (West et al., 1994). Although we did not detect a difference in
apoptosis in NipKD CA1 region compared with WT, we did see differences in the CA1
region after excitotoxic insult. Taken together my results support the hypothesis that
Nipsnap1 may play a neuroprotective role in the brain.

	
  

52	
  	
  

	
  
	
  
Proposed working model
APP is a transmembrane protein that is expressed in developing and mature
brains. Normally, APP is cleaved by α-secretase, which generates APP fragments that
have neuroprotective and neurotrophic properties (Mattson et al, 1993). However, APP
can be aberrantly cleaved by β-secretase, which generates Aβ peptides that are toxic to
neurons. Extracellular aggregation of Aβ peptides are one of the main hallmarks of
Alzheimer’s Disease. Furthermore, this improper cleavage of APP also releases the
intracellular domain of APP, (AICD), which has also been shown to have neurotoxic
effects, reportedly through interactions with nuclear transcription machinery (Kim et al.,
2003). In our lab, a novel neuron-specific mitochondrial protein, Nipsnap1, was found to
interact with both full length APP and the AICD (Tummala et al., 2010). Interestingly,
only mature Nipsnap1 localized in the mitochondria was found to interact with AICD. In
addition, Nipsnap1 was shown to interact with mitochondrial translocases (Tummala et
al., 2010). Interestingly, in AD brains, it was shown that full length and truncated APP
forms a stable ~480 kDA complex with the translocase of the outer mitochondrial
membrane 40 (TOM40) import channel (Devi et al., 2006). The highest levels of
accumulation of APP in mitochondrial import channels occurs in the frontal cortex and
resulted in decreased cytochrome c oxidase activity and increased H202 levels, thus
increased mitochondrial dysfunction. It is possible that this interaction of APP with
mitochondrial transport machinery is mediated through a direct interaction between
Nipsnap1and APP c-terminal region. Indeed, preliminary experiments in our lab have
shown that Nipsnap1 exists in a ~480 kDA mitochondrial complex. Future experiments
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are focused on identifying the Nipsnap1 complex and determining if this complex
includes APP or AICD.
These findings taken together with my observations that a Nipsnap1 deficiency
results in increased amounts to neuronal death supports our working model (Figure 22)
that the AICD could somehow disrupt Nipsnap1 function to make neurons more
vulnerable to death in AD.
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Figure 22. Schematic model of Nipsnap1’s role in the mitochondria. APP is a
transmembrane protein that gets proteolytically cleaved by β-secretase when
mutated. The fragment generated then is cleaved by γ-secretase, which generates
AB plaques, which are toxic to neurons. The Aβ plaques are also taken into the cell
and are toxic to the mitochondria. γ-secretase also generates the AICD, which has
been shown to be targeted and toxic to the mitochondria. Our group has shown that
the AICD interacts with Nipsnap1. I have shown that Nipsnap1 deficiency results in
increased neuron specific death. This is a schematic model showing that the AICD
could possibly disrupt Nipsnap1 function and cause neurons to be more susceptible
to death.
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